| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 12/15/2005 | WO2005117832A1 Liposomal assembly for therapeutic and/or diagnostic use |
| 12/15/2005 | WO2005021556A3 Modified protease inhibitors |
| 12/15/2005 | WO2004089072A9 Non-human mammals and animal cells containing a mutated alpha2/delta1 gene |
| 12/15/2005 | WO2003063759A3 Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
| 12/15/2005 | US20050278020 Medical device |
| 12/15/2005 | US20050277577 Compositions and methods for treating diverticular disease |
| 12/15/2005 | US20050276861 Ex-vivo application of solid microparticulate therapeutic agents |
| 12/15/2005 | US20050276821 Antigen protein and nucleic acid coding for said protein |
| 12/15/2005 | US20050276758 Method for screening agents against human prostate disease |
| 12/15/2005 | US20050276757 Methods of using ZC1 and ZC3 kinase substrate phosphorylation as biomarkers |
| 12/15/2005 | US20050276755 Formulation of Tc and Re carbonyl complexes using stannous ion as the reductant for pertechnetate and perrhenate |
| 12/15/2005 | US20050276750 2-Amino-4-{(2-{(3-amino-3-carboxy-propyl)-[2-(4-methoxy-benzylsulfanyl)-ethyl]-amino}-ethyl)-[2-(4-methoxy-benzylsulfanyl)-ethyl]-amin o}-butyric acid; detection of cells undergoing apoptosis, blood clot, activated inflammatory cells, cell death within tumor, metastases, cell having perturbed membrane |
| 12/15/2005 | DE19507294B4 Verfahren zur Herstellung und Reinigung iodierter Kontrastmittel A process for the preparation and purification of iodinated contrast agents |
| 12/15/2005 | CA2568218A1 Multiple agent therapy for sexual dysfunction |
| 12/15/2005 | CA2567491A1 Immune response assessment method |
| 12/15/2005 | CA2565827A1 Bispecific binding agents for modulating biological activity |
| 12/14/2005 | EP1604689A1 Simultaneous multimodal measurement of physiological function |
| 12/14/2005 | EP1603941A1 Inhibitors of extracellular hsp90 |
| 12/14/2005 | EP1603598A2 Radiolabeled conjugates based on substance p and the uses thereof |
| 12/14/2005 | EP1603451A2 Amyloid plaque as a target for therapeutics that function by blocking or disrupting chitin synthesis or activity |
| 12/14/2005 | EP1603450A2 Type 1 ryanodine receptor-based methods |
| 12/14/2005 | EP1603448A2 Serotonin and catecholamine system segment optimization technology |
| 12/14/2005 | CN1708282A Pharmaceutical identification |
| 12/14/2005 | CN1231483C 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives |
| 12/14/2005 | CN1231257C Use of preparing medicine for raising genitality of female animals with long PENTRAXIN PTX 3 |
| 12/13/2005 | US6974882 Preparation of iodixanol |
| 12/13/2005 | US6974865 C3′ -methylene hydrogen phosphonate oligomers and related compounds |
| 12/13/2005 | US6974791 These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium. |
| 12/13/2005 | US6974668 antitumor agent binds to base DNA or RNA sequence; measure cytolysis of tumor cells; drug screening |
| 12/13/2005 | US6974567 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 12/08/2005 | WO2005116226A2 Nanoparticles comprising rna ligands |
| 12/08/2005 | WO2005116065A1 Labelled adrenomedullin derivatives and their use for imaging and therapy |
| 12/08/2005 | WO2005115997A1 Trimeric macrocyclic substituted aminoisophthalate halophenyl derivatives |
| 12/08/2005 | WO2005115484A1 Use in the medical, diagnostic and phlebological field of a mixture of sterile and physiologically acceptable gases |
| 12/08/2005 | WO2005115483A1 Assay for transmissible spongiform encephalopathies |
| 12/08/2005 | WO2005115482A2 Methods for identifying chemical modulators of ras superfamily gtpase activity |
| 12/08/2005 | WO2005115317A1 Association of chlorin p6 with polyvinylpyrrolidone, a process for its preparation and its uses |
| 12/08/2005 | WO2005115135A2 Mouse model of crohn’s disease and a method to develop specific therapeutics |
| 12/08/2005 | WO2005115134A1 Restless legs syndrome/periodic appendicular dyskinesia model animal |
| 12/08/2005 | WO2005115105A2 Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase |
| 12/08/2005 | WO2005097073A8 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases |
| 12/08/2005 | WO2005087273A3 Extended-linear polymeric contrast agents and their synthesis |
| 12/08/2005 | WO2005041882A3 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs |
| 12/08/2005 | WO2005001906A3 Materials and methods for near-infrared and infrared lymph node mapping |
| 12/08/2005 | US20050271745 Magnetic nanoparticle compositions, and methods related thereto |
| 12/08/2005 | US20050271714 a cationic lipid; and a taxane in a lipid bilayer of the taxane crystal free liposome |
| 12/08/2005 | US20050271673 Trifunctional reagent for conjugation to a biomolecule |
| 12/08/2005 | US20050271663 treating rheumatoid arthritis by using single domain antibody polypeptide construct that binds human TNF- alpha |
| 12/08/2005 | US20050271595 Sanitizing composition and method of preparation |
| 12/08/2005 | US20050271594 Abuse resistent pharmaceutical composition |
| 12/08/2005 | US20050271593 Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof |
| 12/08/2005 | US20050271592 Optical diagnostic and therapeutic agents and compositions |
| 12/08/2005 | US20050271591 Ultrasound contrast agent dosage formulation |
| 12/08/2005 | US20050271590 Treatment of myopia |
| 12/08/2005 | US20050271588 Liposome targeting of matrix metalloproteinase inhibitors |
| 12/08/2005 | US20050271585 Extended conjugated polymers |
| 12/08/2005 | CA2568035A1 Use in the medical, diagnostic and phlebological field of a mixture of sterile and physiologically acceptable gases |
| 12/08/2005 | CA2568019A1 Assay for transmissible spongiform encephalopathies |
| 12/08/2005 | CA2567478A1 Labelled adrenomedullin derivatives and their use for imaging and therapy |
| 12/08/2005 | CA2567429A1 Restless legs syndrome/periodic appendicular dyskinesia model animal |
| 12/07/2005 | EP1602930A2 Use of compounds that bind to GPR49 for diagnosis and treatment of cancer |
| 12/07/2005 | EP1602926A1 Novel means and methods for the treatment of hearing loss and phantom hearing |
| 12/07/2005 | EP1602668A1 Monoclonal antibodies specific to VEGF receptors and uses thereof |
| 12/07/2005 | EP1602649A2 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid derivatives as chelating agents |
| 12/07/2005 | EP1602381A1 Contrast agent for combined modality imaging and methods and systems thereof |
| 12/07/2005 | EP1601970A2 Detection, monitoring and treatment of cancer |
| 12/07/2005 | EP1601965A2 Animal model simulating neurologic disease |
| 12/07/2005 | EP1601949A2 Methods of evaluating caloric restriction and identifying caloric restriction mimetics |
| 12/07/2005 | EP1601775A1 Animal model for the fast identification of pharmaceutical active compounds in vivo |
| 12/07/2005 | EP1601392A1 Compositions for use in embolizing blood vessels comprising high levels of contrast agent |
| 12/07/2005 | EP1601383A2 Method for continuous visualization of a body lumen |
| 12/07/2005 | EP1087794B1 Light application device for photodynamic diagnosis or photodynamic therapy of diseases of the parodontium and teeth |
| 12/07/2005 | EP0755269B1 Contrast agents |
| 12/07/2005 | EP0730434B1 System for harmonic ultrasound imaging with microbubbles |
| 12/07/2005 | EP0697893B1 Neural thread protein gene expression and detection of alzheimer's disease |
| 12/07/2005 | CN2744341Y Air generation capsule for air-barium double contrast radiography of small intestine |
| 12/07/2005 | CN1704124A Isotonicity rapid intestinal tract contrast agent |
| 12/07/2005 | CN1230442C GnRh antagonists being modified in positions 5 and 6 |
| 12/07/2005 | CN1230131C Therapeutic use of polymers |
| 12/06/2005 | US6972122 Contrast enhancement agent for magnetic resonance imaging |
| 12/06/2005 | CA2208274C Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
| 12/01/2005 | WO2005113786A2 Diagnostics and therapeutics for diseases associated with chymase (cma1) |
| 12/01/2005 | WO2005113022A1 System for monitoring gene expression by magnetic resonance imaging using targeted contrast agents |
| 12/01/2005 | WO2005113021A2 Device, system and method for in-vivo analysis |
| 12/01/2005 | WO2005113020A2 Skin test using partially-hydrolysed allergenic proteins |
| 12/01/2005 | WO2005112759A1 A method of enhancing visualization of atherosclerotic plaque |
| 12/01/2005 | WO2005112619A2 Novel gene disruptions, compositions and methods relating thereto |
| 12/01/2005 | WO2005091750A3 Method and materials for use in diagnosing viral myocarditis |
| 12/01/2005 | WO2005065721A3 Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex |
| 12/01/2005 | WO2004068405A3 High contrast optoacoustical imaging using nanoparticles |
| 12/01/2005 | US20050267326 Percutaneous chemical sensor based on fluorescence resonant energy transfer (FRET) |
| 12/01/2005 | US20050267027 Use of erythropoietin for treatment of cancer |
| 12/01/2005 | US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 12/01/2005 | US20050267016 Therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle |
| 12/01/2005 | US20050266483 Novel method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 12/01/2005 | US20050266438 Genetic networks regulated by attenuated GH/IGF1 signaling and caloric restriction |
| 12/01/2005 | US20050266099 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
| 12/01/2005 | US20050266090 Nanoparticular targeting and therapy |
| 12/01/2005 | US20050266067 Nanocell drug delivery system |
| 12/01/2005 | US20050266065 Hydrated lamellar phases or liposomes which contain a fatty monoamine or a cationic polymer which promotes intracellular penetration, and a cosmetic or pharmaceutical composition containing same, as well as a method of screening such a substance |